Advertisement

Ovarian Cancer

Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

May 17, 2021

Ovarian cancer continues to have a poor prognosis with the majority of women diagnosed with advanced disease. Therefore, we undertook the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) t...

Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists.

May 13, 2021

Low-grade serous carcinoma (LGSC) is an infrequent subtype of ovarian cancer, corresponding to 5% of epithelial neoplasms. This subtype of ovarian carcinoma characteristically has molecular features, ...

LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p.

May 13, 2021

Long non-coding RNAs (lncRNAs) have been reported to participate in regulating gene expression and are related to tumor progression. FGD5 antisense RNA 1 (FGD5-AS1) facilitates the progression of vari...

WNT4 balances development versus disease in gynecologic tissues and women's health.

May 10, 2021

The WNT family of proteins are crucial in numerous developmental pathways and tissue homeostasis. WNT4, in particular, is uniquely implicated in development of the female phenotype in the fetus, and i...

[ENTPD5 gene is highly expressed in epithelial ovarian cancer: analysis based on Oncomine database and bioinformatics].

May 10, 2021

To investigate the expression of ENTPD5 in epithelial ovarian cancer and explore its clinical implications.The expression level of ENTPD5 in epithelial ovarian cancer was analyzed based on data from O...

Pre- and post-diagnosis leisure time physical activity and survival following diagnosis with ovarian cancer.

May 10, 2021

Little is known about the influence of pre- and post-diagnosis physical activity on ovarian cancer survival. We investigated this association in two large cohorts, the Nurses' Health Study (NHS) and N...

Dihydroartemisinin regulates apoptosis, migration, and invasion of ovarian cancer cells via mediating RECK.

May 06, 2021

Dihydroartemisinin (DHA) possesses an inhibitory effect on ovarian cancer and promotes reversion-inducing cysteine-rich protein with Kazal motifs (RECK) expression in glioma cells. This study explored...

Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53.

May 06, 2021

Ovarian cancer (OvCA) remains one of the most devastating malignancies, but treatment options are still limited. We report that amphiregulin (AREG) can serve as an effective and safe pharmacological t...

Cisatracurium inhibits the growth and induces apoptosis of ovarian cancer cells by promoting lincRNA-p21.

May 06, 2021

As a common muscle relaxant, cisatracurium has shown good antitumor effect on some tumors. Recent studies reported that cisatracurium could inhibit the progression of colon cancer by upregulating tumo...

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.

May 03, 2021

To explore the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab.A multicenter, phase IV, sin...

ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.

May 03, 2021

Treatment of both platinum resistant high grade (HG) and low-grade (LG) ovarian cancer (OVCA) poses significant challenges as neither respond well to conventional chemotherapy leading to morbidity and...

Platinum-based Chemotherapy and Bevacizumab Instigate the Destruction of Human Ovarian Cancers via Different Signaling Pathways.

May 03, 2021

The standard chemotherapy regimens of ovarian cancer are platinum-based chemotherapy (carboplatin and paclitaxel) and bevacizumab (BEV). However, the effects of BEV alone or combined with carboplatin ...

PAX8 and MECOM are interaction partners driving ovarian cancer.

Apr 29, 2021

The transcription factor PAX8 is critical for the development of the thyroid and urogenital system. Comprehensive genomic screens furthermore indicate an additional oncogenic role for PAX8 in renal an...

IGF-1R anti-idiotypic antibody antagonist exhibited anti-ovarian cancer bioactivity and reduced cisplatin resistance.

Apr 29, 2021

Ovarian cancer is the most deadly gynecological malignant tumor in the world today. Previous studies have shown that insulin-like growth factor-1 receptor (IGF-1R) is closely related to the occurrence...

Development of a high payload, cancer-targeting liposomes of methyl aminolevulinate for intraoperative photodynamic diagnosis/therapy of peritoneal carcinomatosis.

Apr 29, 2021

Methyl aminolevulinate (MAL) is a photosensitizer topically used for photodynamic diagnosis (PDD) and photodynamic therapy (PDT) of skin pre-cancers and cancers. In this study, our goal is to expand t...

A Population Pharmacokinetic Meta-analysis of Veliparib, a PARP Inhibitor, Across Phase I/II/III Trials in Cancer Patients.

Apr 26, 2021

Veliparib (ABT-888) is a poly (ADP-ribose) polymerase (PARP) inhibitor in development for treatment of high-grade ovarian cancer or BRCA-mutated breast cancer in combination with carboplatin and pacli...

Oleuropein reduces cisplatin resistance in ovarian cancer by targeting apoptotic pathway regulators.

Apr 26, 2021

Despite many attempts to treat ovarian cancer, 13,940 individuals perish annually due to this disease worldwide. Chemotherapy is the main approach to ovarian cancer treatment, but the development of d...

Circular RNA circE2F2 promotes malignant progression of ovarian cancer cells by upregulating the expression of E2F2 protein via binding to HuR protein.

Apr 26, 2021

Ovarian cancer (OC) is a gynecological malignancy with a poor prognosis and low survival rate. E2F2 is a transcription activator that plays an indispensable role in cell proliferation and cell cycle p...

Universal access to genetic counseling for women with epithelial ovarian cancer in Nova Scotia: Evaluating a new collaborative care model.

Apr 22, 2021

Women with pathogenic variants in BRCA1/2 have a significantly increased lifetime risk of breast and ovarian cancers. The availability of genetic testing to identify BRCA1/2 carriers is imperative to ...

Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.

Apr 22, 2021

To investigate the relationship between lncRNA PVT1(PVT1) level and PD-L1 expression and their functions in cisplatin resistant epithelial ovarian cancer (CREOC).PVT1 and PD-L1 in ovarian cancer tissu...

SUBSPECIALTIES

Advertisement